To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- NASH
- Interventions
- Drug: BAR502 single doseDrug: Placebo single doseDrug: BAR502 multiple doses
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- BAR Pharmaceuticals s.r.l.
- Target Recruit Count
- 52
- Registration Number
- NCT06705998
- Locations
- 🇨ðŸ‡
CROSS Research S.A. Phase I Unit, Arzo, Switzerland
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- BAR Pharmaceuticals s.r.l.
- Registration Number
- NCT05203367
- Locations
- 🇵🇹
BlueClinical Phase I, Porto, Portugal
© Copyright 2025. All Rights Reserved by MedPath